Lundbeck wins appeal in decade-long IP battle with Sandoz over Lexapro
Intellectual Property 2024-09-20 11:30 pm By Sam Matthews | Melbourne
Please login to bookmark Close

Pharmaceuticals giant Lundbeck has succeeded in overturning IP Australia’s decision granting Novartis unit Sandoz a licence to sell a generic version of top-selling antidepressant Lexapro.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au